New resource available view now
New resource available view now
Recent Post
Related Posts
Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities
Is Neurodegeneration the Root Cause of Alzheimer’s Disease?
By: Laura Sánchez, R&D Chemist Imagine your brain as a bustling city where neurons serve as roads, highways, and communication lines, keeping everything connected and running smoothly. Now picture cracks
POTOMAC, MARYLAND – January 6, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer’s Drug Development
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
New Patent Expands IGC Pharma’s Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer’s Disease